Emerging Novel Therapeutic Agents in the Treatment of Patients with Gastroesophageal and Gastric Adenocarcinoma

Gayathri Anandappa; Ian Chau

doi:10.1016/j.hoc.2017.02.001

Emerging Novel Therapeutic Agents in the Treatment of Patients with Gastroesophageal and Gastric Adenocarcinoma

Hematol Oncol Clin North Am. 2017 Jun;31(3):529-544. doi: 10.1016/j.hoc.2017.02.001. Epub 2017 Mar 22.

Authors

Gayathri Anandappa¹, Ian Chau²

Affiliations

¹ Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK; Department of Medicine, Royal Marsden Hospital, London, UK.
² Department of Medicine, The Royal Marsden Hospital NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK; Department of Medicine, Royal Marsden Hospital, London, UK. Electronic address: [email protected].

PMID: 28501092
DOI: 10.1016/j.hoc.2017.02.001

Abstract

With further understanding of the biology of gastric and gastroesophageal adenocarcinomas, strides are being made to find effective treatments through novel trial designs. This article focuses on the ongoing trials of drugs targeting specific hallmarks of gastric and gastroesophageal cancers, including oncogene addiction proliferative pathways (fibroblast growth factor receptor 2 amplified tumors), stem cell inhibition, apoptotic induction through claudin inhibitors, and matrix metalloproteinase inhibition. In developing novel therapeutics in treatment of patients with gastroesophageal adenocarcinomas, parallel research efforts to refine target population and biomarkers are crucial, and targeting the tumor genomics and microenvironment may be key in improving overall survival.

Keywords: AZD4547; Claudin inhibitors; FGFR2 inhibitors; Gastric adenocarcinoma; Gastroesophageal adenocarcinoma; MMP inhibitors; Napabucasin; STAT3 inhibitors.

Publication types

Review

MeSH terms

Adenocarcinoma* / drug therapy
Adenocarcinoma* / genetics
Adenocarcinoma* / metabolism
Adenocarcinoma* / pathology
Antineoplastic Agents / therapeutic use*
Claudins / antagonists & inhibitors
Claudins / genetics
Esophageal Neoplasms* / drug therapy
Esophageal Neoplasms* / genetics
Esophageal Neoplasms* / metabolism
Esophageal Neoplasms* / pathology
Gelatinases / antagonists & inhibitors
Gelatinases / genetics
Gelatinases / metabolism
Gene Amplification
Humans
Neoplasm Proteins* / antagonists & inhibitors
Neoplasm Proteins* / genetics
Neoplasm Proteins* / metabolism
Neoplastic Stem Cells / metabolism
Neoplastic Stem Cells / pathology
Receptor, Fibroblast Growth Factor, Type 2 / antagonists & inhibitors
Receptor, Fibroblast Growth Factor, Type 2 / genetics
Receptor, Fibroblast Growth Factor, Type 2 / metabolism
Stomach Neoplasms* / drug therapy
Stomach Neoplasms* / genetics
Stomach Neoplasms* / metabolism
Stomach Neoplasms* / pathology

Substances

Antineoplastic Agents
Claudins
Neoplasm Proteins
FGFR2 protein, human
Receptor, Fibroblast Growth Factor, Type 2
Gelatinases